Deutsche Bank Starts Akorn (AKRX) at Buy; Emerging Leader in Niche Generic Drugs

Deutsche Bank initiates coverage on Akorn (NASDAQ: AKRX) with a Buy. PT $11.00.

Deutsche analyst says, "Principally focused on the higher-margin areas of ophthalmology and injectable drugs, including hospital-based critical care and pain management products, Akorn is an emerging niche generic drug company. With a maturing ANDA pipeline (22 filings at FDA, brand value of $2.8B), recent expansion into the OTC ophthalmic segment, in tandem with additional opportunities to enhance its product portfolio through acquisitions, we believe that the company is well positioned for 30%+ annual EPS growth over the next three years."

For more ratings news on Akorn click here and for the rating history of Akorn click here.

Shares of Akorn closed at $8.48 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Starts Hochtief AG (HOT:GR) (HOCFF) at Hold
• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Leerink Starts Freenome Inc. (FRNM) at Outperform